Brigatinib in crizotinib-refractory ALK+ non-small cell...

Lung Cancer 2019 / 01 Vol. 127

Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

Kim, D., Huber, R., Ahn, M., Langer, C., Tiseo, M., West, H., Groen, H., Reckamp, K., Hochmair, M., Leighl, N., Hansen, K.H., Gettinger, S., Paz-Ares Rodriguez, L., Kim, E., Smit, E., Kim, S., Reichma
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
127
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(19)30120-5
Date:
January, 2019
File:
PDF, 55 KB
english, 2019
Conversion to is in progress
Conversion to is failed